Erin Wilson
Stock Analyst at Morgan Stanley
(1.76)
# 3,361
Out of 5,090 analysts
23
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $28 → $22 | $15.97 | +37.76% | 8 | Sep 2, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $157.21 | +365.62% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $184.31 | +108.89% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $225.85 | +17.33% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $548.12 | -62.60% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $185.80 | +34.55% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $21.90 | +73.52% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $27.79 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $572.77 | -40.46% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.36 | +3,870.59% | 4 | Nov 14, 2017 |
Rapid7
Sep 2, 2025
Maintains: Equal-Weight
Price Target: $28 → $22
Current: $15.97
Upside: +37.76%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $157.21
Upside: +365.62%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $184.31
Upside: +108.89%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $225.85
Upside: +17.33%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $548.12
Upside: -62.60%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $185.80
Upside: +34.55%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $21.90
Upside: +73.52%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $27.79
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $572.77
Upside: -40.46%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.36
Upside: +3,870.59%